Human Papillomavirus

House of Lords written question – answered on 28th July 2014.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Shadow Spokesperson (Health), Shadow Deputy Leader of the House of Lords

To ask Her Majesty’s Government what progress the sub-committee on human papilloma virus vaccines of the Joint Committee on Vaccination and Immunisation has made.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

The Human papilloma virus (HPV) sub-committee met for the first time on 20 January 2014 to review available evidence on the impact and cost-effectiveness of potential extensions to the HPV vaccination programme including vaccinating men who have sex with men (MSM) and/or adolescent boys.

The HPV sub-committee will report its findings to the Joint Committee on Vaccination and Immunisation (JCVI) following consideration of on-going studies by Public Health England on the impact and cost-effectiveness of extending HPV vaccination to MSM or adolescent boys. The subcommittee requested that on-going work by Public Health England to model the impact cost effectiveness of targeted MSM vaccination report as early as possible, and advised that an individual based model should be developed to look at the impact and cost effectiveness of universal vaccination of adolescent boys.

In January 2014 the HPV Subcommittee also advised moving from a three dose vaccination schedule to a two dose schedule for adolescent females and this was endorsed by JCVI in February 2014 and will be implemented in September 2014.

The HPV Subcommittee will next be meeting in autumn 2014 to consider the latest evidence for the potential extensions to the HPV vaccination programme.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.